Vitiligo-like depigmentation following neoadjuvant chemotherapy combined with pembrolizumab in early triple-negative breast cancer: a case report.

Authors

Yinglei Deng, Dahua Mao, Shaogang Zhang, Jing Wang

Published in

Frontiers in oncology. Volume 16. Pages 1817257. Epub Jul 20, 2026.

Abstract

Triple-negative breast cancer (TNBC) is a biologically aggressive subtype of breast cancer associated with an unfavourable prognosis. In recent years, the combination of immune checkpoint inhibitors with neoadjuvant chemotherapy has become a standard treatment strategy for selected patients with early-stage TNBC. With the increasing use of immunotherapy, immune-related adverse events (irAEs) have received growing attention, among which cutaneous irAEs are the most frequently reported. However, vitiligo-like depigmentation remains a rare and infrequently described manifestation in the context of breast cancer immunotherapy.
We report the case of a patient with early-stage triple-negative breast cancer who experienced tumour progression following anthracycline- and cyclophosphamide-based neoadjuvant chemotherapy at an outside institution. The patient was subsequently referred to our centre and treated with taxane- and carboplatin-based neoadjuvant chemotherapy in combination with pembrolizumab, resulting in a gradual reduction in tumour size on serial imaging assessments. Surgical resection was subsequently performed, with postoperative pathological evaluation confirming a pathological complete response. Around the fourth cycle of postoperative pembrolizumab maintenance therapy, the patient gradually developed vitiligo-like depigmentation predominantly involving the dorsal aspects of both hands and the perioral region, with additional scattered hypopigmented lesions on the trunk. These cutaneous changes were asymptomatic and did not interrupt the planned course of immunotherapy.
This case suggests that vitiligo-like depigmentation may occur as a rare immune-related cutaneous manifestation in patients receiving pembrolizumab-based therapy for early-stage TNBC. Although this finding has no established predictive value for treatment outcomes in breast cancer, recognising this manifestation may help clinicians distinguish it from other dermatological conditions and avoid unnecessary treatment interruption when the lesions are mild and asymptomatic. Further reports are needed to clarify the incidence, biological basis, and clinical significance of immune-related depigmentation in patients with breast cancer receiving immune checkpoint inhibitors.

PMID:
42548621
Bibliographic data and abstract were imported from PubMed on 04 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.